FDA approves Abbott’s continuous glucose monitoring system

The Food and Drug Administration recently approved the FreeStyle Libre Pro system, a continuous glucose monitoring system developed by Abbott Park, Ill.-based Abbott.

Advertisement

To use the system, clinicians attach a small, disposable sensor on the back of a patient’s arm. The sensor, worn for two weeks, continuously measures glucose and records levels every 15 minutes. At the end of the fourteen days, the patient attends a follow-up appointment where the physician uses a FreeStyle Libre Pro reader to scan the sensor and download the patient’s glucose results stored in the sensor.

“This technology is groundbreaking because continuous glucose monitoring systems for professional use have been long considered a niche, cumbersome, and expensive technology for mostly Type 1 patients,” said Eugene Wright, Jr., MD, physician at Duke Southern Regional Area Health Education Center in Fayetteville, N.C. “The FreeStyle Libre Pro system changes this paradigm not only because of the unique technology but because it doesn’t require fingerstick calibration, is easier to use, more affordable, and is more accessible to people with diabetes.”

More articles on supply chain:

Why patient advocacy groups are silent about high drug prices
Amazon wants to scale up distribution network to compete with FedEx, UPS
5 things to know about the international X-ray gap

 

 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.